List of Excipients in Branded Drug ANZUPGO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
LEO Pharma Inc	ANZUPGO	delgocitinib	50222-280	BENZYL ALCOHOL	2030-07-23
LEO Pharma Inc	ANZUPGO	delgocitinib	50222-280	BUTYLATED HYDROXYANISOLE	2030-07-23
LEO Pharma Inc	ANZUPGO	delgocitinib	50222-280	CETOSTEARYL ALCOHOL	2030-07-23
LEO Pharma Inc	ANZUPGO	delgocitinib	50222-280	CITRIC ACID MONOHYDRATE	2030-07-23

ANZUPGO Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

ANZUPGO is a delgocitinib 20 mg/g topical cream approved in the European Union for moderate-to-severe chronic hand eczema in adults. Its excipient system uses an oil-in-water cream architecture combining emollients, humectants, emulsifiers, buffering agents, and purified water. The strongest commercial opportunities are differentiated topical presentations, regional manufacturing, excipient substitution supported by equivalence data, and delivery systems that improve adherence without materially increasing systemic exposure.

What is ANZUPGO and how is it regulated?

ANZUPGO contains delgocitinib, a pan-Janus kinase inhibitor administered topically to affected hand skin. The European Commission granted marketing authorization in September 2024 following the European Medicines Agency review.[1]

Attribute	ANZUPGO profile
Active ingredient	Delgocitinib
Strength	20 mg/g cream
Therapeutic area	Chronic hand eczema
Marketing authorization holder	LEO Pharma A/S
Route	Cutaneous
EU indication	Moderate-to-severe chronic hand eczema in adults when topical corticosteroids are inadequate or inappropriate
Recommended use	Applied twice daily to affected skin
Treatment limitation	Treatment should be discontinued if there is no improvement after 12 weeks
Initial EU authorization	2024
Dosage form	Cream
Biologic or small molecule	Small molecule
Biosimilar pathway	Not applicable

The product is not a biologic. Biosimilar competition is therefore irrelevant. Any follow-on product would use a generic, hybrid, abridged, or national regulatory pathway rather than a biosimilar pathway.

What excipients are used in ANZUPGO cream?

The European product information identifies the following excipients:

Excipient	Primary formulation role	Commercial relevance
White soft paraffin	Occlusive emollient; reduces transepidermal water loss	Supports barrier repair and hand-eczema tolerability
Liquid paraffin	Oil-phase emollient and spreading aid	Helps create a persistent, lubricious film
Glycerol	Humectant	Increases hydration of the stratum corneum
Cetostearyl alcohol	Consistency agent and co-emulsifier	Builds viscosity and cream structure
Macrogol cetostearyl ether	Nonionic emulsifier	Stabilizes the oil-in-water emulsion
Propylene glycol	Humectant and solvent	Supports hydration and active distribution; may raise irritation concerns in sensitive skin
Sodium citrate	Buffer component	Helps maintain formulation pH
Citric acid monohydrate	pH adjustment and buffer component	Controls pH during manufacture and storage
Purified water	Continuous aqueous phase	Provides the cream vehicle

The formulation is strategically conservative. It relies on widely used dermatological excipients rather than a highly novel delivery platform. That choice can simplify scale-up and sourcing, but it also limits the extent to which the excipient composition alone creates a durable competitive barrier.

How does the ANZUPGO excipient system support topical delivery?

The formulation has four functional layers.

Barrier support

White soft paraffin and liquid paraffin create an occlusive lipid film. This is commercially relevant because chronic hand eczema is associated with barrier disruption, dryness, fissuring, and repeated exposure to water and irritants. An occlusive base can improve local comfort and reduce water loss independently of delgocitinib pharmacology.

Hydration

Glycerol and propylene glycol provide humectancy. Hydration can improve flexibility of damaged skin and may support distribution of delgocitinib across the superficial epidermal barrier.

Propylene glycol is a functional excipient rather than a passive filler. It can act as a solvent, humectant, and penetration-supporting component. Its concentration and exposure profile must be controlled because propylene glycol can cause irritation or contact dermatitis in susceptible patients.

Emulsion structure

Cetostearyl alcohol and macrogol cetostearyl ether establish the cream's rheology and physical stability. They influence:

• Spreadability over fissured or inflamed skin
• Residual film after application
• Phase stability
• Wash-off behavior
• Dose uniformity from the tube
• Patient perception of greasiness and absorption

For a hand-eczema product, these attributes have direct commercial importance. Patients frequently wash their hands, work with gloves, and avoid products that remain excessively greasy.

pH control

Citric acid and sodium citrate provide a buffer system. pH affects delgocitinib solubility, chemical stability, preservative performance where applicable, and skin tolerability. A formulation change that alters pH can change both product quality and clinical performance even when the active concentration remains 20 mg/g.

What formulation characteristics are protected by the ANZUPGO product?

The approved product information establishes the marketed composition and quality specifications, but it does not by itself show that every excipient combination is protected by a granted patent. The principal potential IP categories are:

1. Delgocitinib compound and salt patents.
2. Topical pharmaceutical compositions containing delgocitinib.
3. Cream systems with defined excipient classes or concentration ranges.
4. Methods of treating chronic hand eczema with topical delgocitinib.
5. Manufacturing processes that control particle size, dissolution, homogenization, pH, viscosity, or content uniformity.
6. Packaging systems that limit degradation or preserve dose delivery.

A competitor could avoid a narrow composition claim by changing the emulsifier, oil phase, humectant, buffer, or dosage form. That strategy would still require proof that the substitute formulation has comparable product performance and clinical relevance.

The commercially important question is not whether an excipient is listed in the public SmPC. It is whether a patent claim covers a concentration range, functional relationship, process parameter, or use of that excipient with delgocitinib. Public regulatory documents do not establish the full scope of LEO Pharma's global patent estate.

When could ANZUPGO lose EU regulatory exclusivity?

ANZUPGO's EU marketing authorization began in 2024. For a new active substance, the European Union generally provides eight years of regulatory data protection followed by two years of market protection. A further one-year extension can apply if the authorization holder obtains approval for a significant new therapeutic indication with meaningful clinical benefit.[2]

Exclusivity category	Indicative timing from 2024 authorization
Regulatory data protection	Approximately through 2032
Market protection	Approximately through 2034
Potential one-year indication extension	Potentially through 2035
Patent or supplementary protection certificate	Separate analysis required

These dates are regulatory estimates, not confirmed patent expiry dates. Patent expiration, supplementary protection certificates, pediatric extensions, and national implementation issues can produce a different practical entry date.

Because ANZUPGO is a topical small molecule, EU generic or hybrid applicants could target the cream after the relevant protection period. They would need to address pharmaceutical equivalence, topical performance, quality, and any valid method-of-use or formulation patents.

What Orange Book and FDA status does ANZUPGO have?

ANZUPGO received EU authorization, not an FDA approval identified in the cited European regulatory record. A U.S. commercial launch would require an FDA-approved application for delgocitinib cream or another qualifying product.

No U.S. Orange Book patent listing should be assumed from the EU authorization. Orange Book listing depends on an approved FDA application and the sponsor's submission of eligible patents under U.S. listing rules.[3]

The U.S. opportunity is therefore open from a market-access perspective, but it is not a low-risk opportunity. A U.S. sponsor would need to address:

• FDA requirements for chronic hand eczema
• Topical JAK safety assessment
• Local and systemic exposure
• Long-term use and retreatment
• Formulation sameness or suitability for an abbreviated pathway
• Pediatric development obligations
• Patent rights owned or licensed by LEO Pharma

The FDA's class-wide JAK safety communications for certain systemic products increase the importance of exposure characterization for topical delgocitinib. A low systemic exposure profile could support differentiation, but it would not eliminate the need for product-specific FDA review.[4]

What commercial opportunities exist in ANZUPGO excipients?

Preservative-free or lower-irritancy formulations

A reformulation that reduces irritation potential could target patients with fissuring, barrier damage, or concomitant contact sensitivity. Propylene glycol is the most obvious excipient requiring scrutiny, although removing it could affect solubility, hydration, rheology, and drug release.

A commercial substitute could use a different solvent or humectant system, but the change would need comparative data for:

• Delgocitinib assay and degradation products
• Particle or droplet distribution
• Viscosity and spreadability
• In vitro release
• Skin permeation
• Local tolerability
• Microbiological quality

Less greasy cream systems

The paraffin-rich base may support barrier repair but can be perceived as greasy. A lighter emulsion, gel-cream, lotion, or sprayable vehicle could improve daytime adherence, particularly for healthcare workers and patients who wash their hands frequently.

The key tradeoff is that reducing occlusion may improve cosmetic acceptability while reducing residence time and barrier support. A successful product would need to maintain topical exposure without increasing systemic absorption.

Faster-absorbing dosage forms

A gel-cream or emulgel could provide faster rub-in and lower residue. This may support use during working hours, while the original cream remains positioned for evening application or severe dryness.

Potential technical barriers include delgocitinib solubility, crystallization during storage, altered release kinetics, and instability caused by solvent changes.

High-adherence packaging

Packaging is an underdeveloped commercial opportunity. A metered-dose pump, airless container, or unit-dose system could improve hygiene and dosing consistency compared with a conventional tube. Packaging claims can also address:

• Reduced contamination after repeated hand contact
• Better protection against water and oxygen
• More accurate application quantities
• Easier use for patients with painful fissures

Packaging changes can create a differentiated product even when the active and excipient system remain close to the reference formulation.

Regional supply and dual sourcing

The excipients are common pharmaceutical-grade materials, which reduces dependence on highly specialized suppliers. That creates opportunities for:

• Regional manufacture of cream bulk
• Dual sourcing of paraffins, glycerol, and emulsifiers
• Local fill-finish operations
• Contract development and manufacturing services
• Supply agreements tied to volume, quality, and change-control performance

The highest supply-chain risks are likely to involve quality consistency, microbial control, tube compatibility, and process reproducibility rather than scarcity of the individual excipients.

How strong is the ANZUPGO formulation moat?

The formulation moat is moderate rather than inherently high.

Strengths

• The vehicle is compatible with the barrier-compromised skin associated with chronic hand eczema.
• The excipient system uses established dermatological materials with known manufacturing behavior.
• Delgocitinib's topical performance depends on the complete formulation, not only the active ingredient.
• Changes in pH, solvent balance, emulsion structure, and viscosity could affect bioavailability and tolerability.
• A clinically validated product has an advantage over untested excipient alternatives.

Weaknesses

• Most listed excipients are widely available and difficult to monopolize broadly.
• A competitor may design around a narrow composition claim.
• Cream manufacture is accessible to experienced topical CDMOs.
• Generic applicants can pursue a different but therapeutically equivalent formulation.
• The absence of a complex device or biologic manufacturing process lowers technical entry barriers.

The strongest defensible position would combine active-ingredient rights, method-of-use claims, formulation claims, manufacturing controls, and clinical data. Excipient selection alone is unlikely to provide the full commercial moat.

What generic launch scenarios exist for ANZUPGO?

Scenario	Likely product strategy	Main barrier
Direct cream generic	Match strength and dosage form	Equivalence and patent clearance
Formulation-around product	Replace solvent, emulsifier, or oil phase	Clinical and pharmaceutical equivalence
Alternative topical dosage form	Gel, lotion, foam, or spray	New development and regulatory risk
Licensed regional product	Obtain rights from LEO Pharma	Economics and territorial rights
U.S. development program	File a standalone FDA application	Safety, efficacy, and exclusivity
Hospital or specialist channel product	Focus on adherence or occupational use	Limited market scale

The most credible near-term commercial route is a formulation-around product after regulatory and patent barriers permit entry. A radically different delivery system could be valuable, but it would likely require a larger clinical and regulatory investment.

Which companies could compete with ANZUPGO?

ANZUPGO competes in chronic hand eczema against topical corticosteroids, calcineurin inhibitors used off label or in selected settings, phototherapy, systemic immunomodulators, and other topical or oral JAK-pathway products.

Relevant competitive categories include:

• LEO Pharma, as the ANZUPGO sponsor
• Companies commercializing topical corticosteroids
• Developers of topical PDE-4 inhibitors
• Developers of topical or oral JAK inhibitors
• Dermatology companies with barrier-repair creams and prescription emollients
• Generic manufacturers with topical cream manufacturing capacity

Competition will depend on efficacy, recurrence control, safety monitoring, cosmetic acceptability, reimbursement, and physician willingness to use a topical JAK inhibitor for hand disease.

What licensing and partnership opportunities are available?

Potential transaction structures include:

1. Regional licensing of ANZUPGO rights outside LEO Pharma's core markets.
2. Co-development of a lighter or preservative-reduced formulation.
3. Excipient-platform licensing for improved skin delivery.
4. CDMO supply agreements covering bulk cream and fill-finish.
5. Packaging partnerships for metered dosing or airless delivery.
6. Combination regimens pairing delgocitinib with barrier-repair technology.

The most attractive partner targets are companies with dermatology sales infrastructure, topical formulation expertise, reimbursement access, or manufacturing assets. An excipient supplier would have greater negotiating leverage if it owns a validated, differentiated delivery platform rather than merely supplying commodity glycerol, paraffin, or emulsifier.

Key Takeaways

• ANZUPGO is a delgocitinib 20 mg/g cream authorized in the EU in 2024 for adult moderate-to-severe chronic hand eczema.
• Its excipient system combines paraffin emollients, glycerol and propylene glycol humectants, cetostearyl alcohol and macrogol cetostearyl ether emulsifiers, citrate buffering agents, and water.
• The current formulation is clinically practical but not structurally difficult to reproduce.
• The highest-value opportunities are lighter cream systems, lower-irritancy vehicles, preservative-free designs, improved packaging, and regional supply partnerships.
• Propylene glycol, occlusion, pH, rheology, and drug-release behavior are the main formulation variables for competitive development.
• EU regulatory protection is expected to extend approximately through 2032 for data protection and 2034 for market protection, subject to the applicable exclusivity record and any extensions.
• No EU authorization automatically creates a U.S. Orange Book listing.
• Biosimilar competition does not apply because delgocitinib is a small molecule.
• The strongest IP position would combine formulation, method-of-use, manufacturing, and active-ingredient claims.

FAQs

Can ANZUPGO be reformulated without changing delgocitinib strength?

Yes, but a reformulation would need to demonstrate acceptable quality, stability, topical release, skin permeation, and local tolerability. Changing the vehicle can change clinical performance even when the active concentration remains 20 mg/g.

Is propylene glycol essential to ANZUPGO?

The public product information lists propylene glycol as an excipient, but it does not establish that propylene glycol is indispensable. Removing or replacing it could affect delgocitinib solubility, hydration, release, and tolerability.

Could ANZUPGO be developed as a foam?

A foam could improve spreadability and cosmetic acceptability, but it would be a substantial dosage-form change. The sponsor would need to establish dose delivery, formulation stability, skin exposure, and clinical comparability.

Are ANZUPGO excipients subject to pharmaceutical patent protection?

Individual excipients such as glycerol, paraffin, and cetostearyl alcohol are established materials. Protection, if available, would more likely arise from a combination, concentration range, functional formulation relationship, manufacturing process, or use claim.

What is the most commercially attractive ANZUPGO line extension?

A lower-residue, faster-absorbing cream or gel-cream is the clearest commercial candidate. It could address daytime adherence while preserving the original occlusive cream for patients with severe dryness or fissuring.

References

1. European Medicines Agency. (2024). Anzupgo: EPAR - Product information. https://www.ema.europa.eu/
2. European Commission. (2024). Regulation (EC) No 726/2004 and pharmaceutical legislation on data and market protection. https://health.ec.europa.eu/
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
4. U.S. Food and Drug Administration. (2021). FDA requires warnings about increased risk of serious heart-related problems, cancer, blood clots, and death for JAK inhibitors. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-problems-cancer-blood-clots-and-death